S. Cedrés

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Aleix Prat, Alejandro Navarro, Laia Paré et al. · Cancer Research · 2017 · 468 citations

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 422 citations

Surgical Oncology, Malignant Disease, Relapsed Malignant Mesothelioma +8

Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer

S. Cedrés, Davis Y. Torrejon, A. Martínez et al. · Clinical & Translational Oncology · 2012 · 300 citations

Cancer Immunosurveillance, Granulocyte, Medicine +7

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia et al. · PLoS ONE · 2015 · 213 citations · Full text

Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)

S. Cedrés, Isaac Núñez, Marina Longo et al. · Clinical Lung Cancer · 2011 · 210 citations

Prognostic Biomarkers, Medicine, Pathology +7